Delivery Order SPE2DB24D1021-SPE2DB25FEYUW
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $3,326.60 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count). The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. Performance is scheduled to conclude by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $18,060.83 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units). This firm fixed-price delivery order, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count packaging) with a ceiling value of $25,134.02. This firm fixed-price delivery order, which is not set-aside, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be performed and delivered from...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $4,328.04 under firm fixed-price terms, with an ultimate completion date of July 31, 2025. The pharmaceutical products will be delivered to the contracting location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $3,759.95 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets in quantities of 30, with an ultimate completion date of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be performed from the contractor's facility...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron ODT 4 MG tablets (30-count) with a contract ceiling value of $1,512.72. This firm fixed price delivery order, which is set to be completed by August 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The award was competitively...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,882.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded and completed on August 8, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $27,766.85 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEYUWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,466.96 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen Drug Corp supplies a broad range of medications and medical supplies to support military and veteran healthcare systems. The company's contract awards with the DLA demonstrate extensive capability in fulfilling federal pharmaceutical needs across multiple therapeutic domains, including oncology, neurology, pain management, and other specialties. The current delivery order for Ondansetron—an antiemetic medication commonly used in military medical settings—exemplifies the company's role in supplying essential medications through the DLA's global pharmaceutical support network serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.5k | 7/18/25 |